Skip to search formSkip to main contentSkip to account menu

TAK 637

Known as: (aR,9R)-7-(3,5-bis(trifluoromethyl)benzyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-(1,4)diazocino(2 1-g)(1,7)naphthyridine-6,13-dione, TAK-637, TAK637 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Naphthyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BOWEL, SYNDROME AND METHODS THEREOF
The Merck Manual, 17th edition, (1999), p. 312.* M. Jarrett, RN, Phd., et al., “Sleep Disturbance Influences Gastrointestinal… 
2004
2004
Effects of TAK-637 on NK(1) receptor-mediated mechanisms regulating colonic secretion.
2002
2002
Peripheral activity of a new NK1 receptor antagonist TAK-637 in the gastrointestinal tract.
Pathways controlling gastrointestinal function involve the activation of neurokinin NK1 receptors by substance P (SP) under… 
2001
2001
Effect of TAK-637, a tachykinin NK1-receptor antagonist, on lower urinary tract function in cats.
The effect of TAK-637 ((aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H[1,4… 
Review
2001
Review
2001
TAK-637. Takeda.
Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence… 
2001
2001
Microbial synthesis of three metabolites of a tachykinin receptor antagonist, TAK-637.
2000
2000
Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs.
1999
1999
Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea pig.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)